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Introduction   
   
Central giant cell granuloma (CGCG) is an uncommon benign intraosseus lesion that 
occurs almost exclusively in jaws, introduced for the first time by Jaffé in 1953
1
. The 
clinical behavior of CGCG is variable. It ranges from slow-growing, asymptomatic 
swelling to an aggressive lesion which manifests with pain. The etiopathogenesis has 
not been clearly established but it has been suggested that it is the result of an 
exacerbated reparative process related to previous trauma and intraosseous 
haemorrhage that triggers the reactive granulomatous process. The CGCG may occur 
at any age, but it is most commonly seen in the first three decades. 37.5% of CGCGs 
are located in the incisor, canine, and premolar regions of the mandible (Kaffe et al, 
1996). CGCG of the jaw is usually unifocal and have traditionally been treated 
surgically; the common therapy being curettage or resection (Kermer et al, 1994; 
Eisenbud et al, 1988)
2,3,4
. 
 
Case report 
A 12 year old boy reported to the department of Oral Pathology and Microbiology, 
Subharti Dental College with a painless swelling on the right side of the face since 
three months. Patient gave a history of fall from the bed three months back and 
developed pain and swelling in the right maxillary anterior region. He consulted a local 
doctor and on whose medications, the pain subsided but the swelling gradually 
increased. Past medical history was not significant and the patient was moderately 
built and nourished. Extra oral examination showed diffuse swelling extending from 
upper lip to ala-tragus line causing obliteration of nasolabial fold and resulting in 
facial asymmetry (Figure 1). Skin overlying swelling was normal with no raised 
temperature. Intra oral examination revealed the presence of a painless, firm swelling 
of 2cm to 2.5cm in size on the right anterior maxillary ridge extending from labial 
frenum to the right corner of the mouth with well defined borders and it was fixed to 
underlying bone. There 
was no sign of pulsations or fluctuation on palpation (Figure 2). The adjacent dentition 
and the oral 
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Abstract      
                         
Central giant cell granuloma (CGCG) is a benign reactive lesion rather than benign neoplastic  
lesion. In 70% of cases, it is seen in mandible and the remaining 30% occurs in maxilla. 
Females are affected more than males and commonly seen in children and young adults. The 
etiology is still completely unknown but thought to be of a reactive process to some 
unknown stimuli. However, it has radiographic features similar to some neoplastic lesions. The 
incidence in the general population is very low.  Central giant cell granuloma is characterized 
by the presence of multinucleated giant cells of varying shapes and sizes, fibrous tissue, 
vascular channels and macrophages. We report a case of central giant cell granuloma in the 
right anterior maxillary region of a 12 year old boy, who develop a painless swelling on the 
right side of the face since three months and gave a history of trauma at the same time. The 
patient was treated surgically and one year follow up did not show any sign of recurrence. 
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Figure1: Swelling on the right side of the face 
 
Figure2: Intraoral swelling on the right anterior maxillary 
ridge 
 
Figure3: H&E(10X) showing multinucleated giant cells 
underlying bone. There was no sign of pulsations or 
fluctuation on palpation (Figure 2). The adjacent 
dentition and the oral mucosa did not reveal any 
abnormality. Radiograph showed unilocular radiolucency 
on the anterior maxillary region. Thus a clinical diagnosis 
of ossifying fibroma, central giant cell granuloma, 
ameloblastoma and fibrous dysplasia was made. 
Histopathological examination revealed a highly cellular 
fibrous stroma with numerous multinucleated giant cells 
of varying sizes and shapes and multiple vascular 
channels (Figure 3). Thus a final diagnosis of central 
giant cell granuloma was made. 
 
 
DISCUSSION 
A Giant cell granuloma (GCG) is a rare benign lesion. In 
the head and neck region its incidence is reported to be 
0.00011%. It usually affects the mandible in 70% of cases 
and the maxilla in the remaining 30%. WHO defined GCG 
histology as intraosseous lesions consisting of cellular 
fibrous biological tissue, containing multiple 
hemorrhagic foci, aggregation of multinucleated giant 
cell, and occasionally trabeculae of woven bone. There 
are several ways to classify GCG. First, the disease can be 
classified as central (CGCG) or peripheral (PGCG). CGCG 
is bone based and usually occurs in the mandible, 
maxilla, temporal bone and paranasal sinuses. Cases of 
CGCG of hard palate are rare in the literature. Peripheral 
is based on biologic tissue and affects frontal alveolar 
mucosa and gingival mucosa. Even though the 
histopathogenesis of CGCG, PGCG, and Giant cell tumor 
(GCT) of the long bones are identical, both CGCG and 
PGCG have a less aggressive biologic behavior than the 
GCT of long bone
5,6
. 
Central giant cell granuloma is a non-neoplastic 
proliferative lesion of unknown etiology. It occurs most 
commonly in the mandible than in the maxilla. But our 
case involved the maxilla. Most mandibular lesions occur 
anterior to first molars and often cross the midline. It 
strikingly occurs more commonly on the right side than 
left side as seen in our case. Central giant cell granuloma 
also occurs in other bones of the facial skeleton and 
cranial vault. It rarely occurs outside the craniofacial 
bones, but it has been described in the short tubular 
bones of hands and feet
7
. In most of the cases, females 
have more predilection than males in the ratio of 2:1. It 
occurs most commonly in children or young adults. Our 
case was seen in a boy of 12 years of age. 
The etiopathogenesis of the CGCG of jawbones has not 
been clearly established but it has been suggested that it 
is the result of an exacerbated reparative process related 
to previous trauma or inflammation and intraosseous 
haemorrhage that triggers the reactive granulomatous 
process. Donoff and Rosenberg discussed a case record 
of an uncomplicated extraction because of pericoronitis 
in the area of the lesion and claimed the local changes in 
the blood flow throughout the bone and local bone 
dysplasia could be probable etiologic factors
8
. Unal et al 
presented a 12 year-old girl CGCG in the mandible 
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caused by a molar tooth extraction and explained the 
pathogenesis by a traumatic aetiology
9
. 
In our case also there was a clear history of trauma and 
thereafter the patient developed a swelling. Recent 
interest in the pathogenesis of the disease is increasing 
as studies for possible medical therapies are emerging. 
The target of therapeutic compounds has been to gain 
control over the proliferation of mononuclear spindle 
cell. Although prominent on microscopy, giant cells are 
not the proliferating cells but the mononuclear spindle 
cells are. These cells also recruit RBC, induce osteoclast 
activity in giant cells, and express Receptor Activator of 
Nuclear Factor-kB (RANK). RANK-osteoprotegin 
antagonist stimulates initiation of resorption. Still 
untested on human beings. MDM2 protein/gene may be 
over-expressed in GCTs and CGCGs. This protein, which 
promotes proliferation through p53 binding, is the only 
cell cycle associated protein determined to be over-
expressed. The p53 gene does not appear to be mutated 
in these lesions. p63 may be a useful biomarker to 
differentiate giant cell tumor of bone from central giant 
cell granuloma and other giant cell-rich tumors, such as 
giant cell tumor of tendon sheath and pigmented 
villonodular synovitis. The conspicuous expression of 
proliferating cell nuclear antigen (PCNA) suggests that 
the proliferative component of CGCG would be 
represented by a mesenchymal stromal cell which had 
the capacity to differentiate along fibroblast/ osteoblast 
lines
10
.  
Expression of the c-Src gene has been implicated in the 
development of CGCG, GCT and cherubism (Wang et al, 
2006)
11
. In addition, histologically identical lesions occur 
in patients with known genetic defects such as 
cherubism, Noonan syndrome, or neurofibromatosis 
type 1. Central giant cell granuloma has been shown in a 
report to be further associated with a reciprocal 
translocation t (X; 4) (q22; q31.3) (Buresh et al, 1999)
12
. 
CD68, a transmembrane glycoprotein and a  monocyte-
macrophage lineage marker has been often used in the 
investigation of giant cells suggesting the existence of a 
histiocyte/macrophage origin for some of the cellular 
components of CGCG and GCT
13
. Accordingly, Liu, et al.
 
(2003) verified the expression of vacuolar H
+
-ATPase (V-
ATPase), carbonic anhydrase II (CA II), cathepsin K, MMP-
9 and tartarate-resistant acid phosphatase (TRAP) in 
multinucleated giant cell of CGCG, thus confirming the 
characteristics of an osteoclastic phenotype
14
. Vered, et 
al. (2006) states that VEGF and bFGF expression could be 
related to stimulation of osteoclastogenesis in CGCG, 
suggesting that high levels of VEGF- and bFGF-
producing cells in a CGCG, would be related to a more 
aggressive biological behavior
15
. 
Giant cells have calcitonin receptors that are inhibited by 
calcitonin thereby inhibiting osteoclastogenesis. 
Interferons have anti angiogenic effect and cause 
inhibition of bone resorption. Intralesional injections of 
corticosteroids is believed to inhibit the bone resorption 
and proliferation and differentiation to osteoclasts. 
Although there is extensive RBC extravasation the 
proliferating cells are not endothelial cells and so there is 
little role for antiangiogenic drugs such as VEGF
16
. 
The clinical behaviour of CGCG varies. Nonaggressive 
lesion is usually slow growing and asymptomatic, does 
not show cortical resorption by the lesion or root 
perforation in teeth affected, and it is significantly less 
likely to recur than the aggressive type. Aggressive 
lesions, is usually found in younger patients and is 
painful, grows rapidly, is larger overall, often causes 
cortical perforation and root resorption and has a 
tendency to recur. The radiological appearance of CGCG 
is variable. Usually the lesion appears as a unilocular or 
multilocular radiolucency. It may be well-defined or ill-
defined and shows variable expansion and destruction of 
the cortical plate. The radiological appearance of the 
lesion is not pathognomonic and may be confused with 
that of many other lesions of jaws. The final diagnosis 
eventually rests on histopathology because the clinical 
and radiological features are not specific
4,17
. 
Histologically, CGCG contain focal arrangements of giant 
cells within a vascular stroma with thin-walled capillaries 
adjacent to the giant cells as seen in our case. There is a 
spindle cell stroma which may well be the cell of origin. 
The absence of perivascular cuffing, as seen in our case 
can help differentiate CGCG from cherubism. Presence of 
foreign body type giant cell and absence of stromal 
tumour cells differentiate CGCG from a GCT. 
‘Solid‘aneurysmal bone cysts (ABC) are true benign 
neoplasms containing giant cells while trauma causing 
intramedullary hemorrhage has been implicated in the 
past as the etiology. Normal serum calcium, parathyroid 
hormone, alkaline phosphatase and phosphorous levels 
distinguish CGCG from other conditions like Brown 
tumour of hyperparathyroidism. 
Cherubism is a self limiting condition, but giant cell 
granulomas can be aggressive with a tendency to recur 
and hence require treatment
17
. Our differential list 
should also include ameloblastoma and odontogenic 
myxoma. In contrast, ameloblastoma tends to occur in 
older age group, posterior in the mandible, and have 
well-defined, curved septa; whereas,CGCG has wispy ill-
defined trabeculation. 
Odontogenic myxoma does not cause much expansion, 
occurs in older age group, and has well-defined septa. 
The rate of recurrence varies between 13-49%. Whitaker 
and Waldron reported a mean interval between 
diagnosis and initial treatment and treatment of a 
recurrence was 21 months, and stated that very few 
recurrences were manifested after 2 years of initial 
treatment. The most reliable factors related to an 
increased risk of recurrence include clinical activity of 
lesions (72% of recurrence in the aggressive forms, 3% of 
recurrence in the nonaggressive forms), younger 
patients, demonstrated perforation of cortical bone and 
tumour size
18
. In the case presented, the patient was a 
young boy and one year follow up did not show any sign 
of recurrences. There have been studies suggesting that 
the greater functional surface area occupied by giant 
cells and larger relative size of giant cells may identify 
tumours with aggressive behavior. Recently, Kruse-Loser 
84 
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et al also proved that the aggressive variant of CGCG 
presented a high number of giant cells, an increased 
mitotic activity, and a high fractional surface area. Clinical 
course of CGCGs from known histological or 
immunohistochemical features is not predicted
5,19
. 
An unusual case of idiopathic bilateral case of central 
giant cell reparative granuloma of the angulus mandible, 
has also been reported in a12 year old girl
20
. 
CGGC is considered a non reparative lesion that destroys 
and grows if it is not treated. Traditionally management 
has been surgical by means of excision by curettage, 
which has been associated with a low recurrence rate in 
the well- located lesions. Curettage with peripheral 
ostectomy and bone resection is reserved for 
recurrences. Eisebund et al used the technique of 
curettage or curettage plus peripheral ostectomy
4
. Unal 
et al recommended microdrill with diamond burr to 
obtain margins of security after removing the lesion and 
filled the cavity with iliac crest chips
9
. The most 
aggressive or recurrent lesions can require en bloc bone 
resection and reconstruction, since it can determine a 
bone defect and teeth loss. 
Becelli et al described a case treated by means of 
excision of a mandibular CGCG, reconstruction using 
autogenous iliac crest graft, dental implants and 
overdenture prosthesis. Surgical curettage was the 
treatment performed in our case. Non surgical 
approaches include intralesional corticoids or systemic 
calcitonins that inhibit the osteoclastic activity. Other 
non surgical treatments include interferon-alpha or 
bifosphonates. Paediatric patients necessitate 
conservative management to prevent long term 
developmental defects. An equal part of triamcinolone 
acetonide (10mg/ ml) and 0.5% bupivacaine injected into 
the lesion for a period of 11 weeks has been shown to be 
effective in a child patient. 
Calcitonin nasal spray 200 U/spray once or twice daily 
was reported to be safe and effective for the treatment 
of CGCG. These can be used for a long term to achieve 
healing 
21,22
. 
Conservative treatments have shown varying degrees of 
success and, when successful, have reduced the necessity 
for reconstructive surgery. 
 
CONCLUSION 
Central giant-cell granuloma (CGCG) is a benign 
condition of the jaws. It is twice as likely to affect women 
and is more likely to occur in 20–40 year old people. 
Central giant-cell granulomas are more common in the 
mandible and often cross the midline. Histologically 
identical lesions occur in patients with known genetic 
defects such as cherubism, Noonan syndrome, or 
neurofibromatosis type 1. Surgical curettage or, in 
aggressive lesions, resection, is the most common 
therapy. However, when using surgical curettage, 
undesirable damage to the jaw or teeth and tooth germs 
is often unavoidable and recurrences are frequent. 
Therefore, alternative therapies such as injection of 
corticosteroids in the lesion or subcutaneous 
administration of calcitonin or interferon alpha are 
described in several case reports with variable success. 
The long term prognosis of giant-cell granulomas is 
good and metastases do not develop. Nevertheless, 
recurrences of CGCG are not uncommon and can be 
seen in upto 46% of cases
23
. 
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